US Pharma MarketingThe post First patient dosed in Molecular and Orano Med’s MP0712 trial appeared first on Clinical Trials Arena.
First patient dosed in Molecular and Orano Med’s MP0712 trial
Molecular Partners and Orano Med have dosed the first patient in the Phase I/IIa trial assessing MP0712, a DLL3-targeting radio-DARPin drug candidate. Initial data is anticipated in 2026, with comprehensive safety and efficacy findings projected for 2027. MP0712 targets the tumour-associated DLL3 protein in over 85% of SCLC tumours. Credit: bangoland / Shutterstock.com. Molecular Partners and Orano Med have dosed the first patient in the Phase I/IIa trial assessing MP0712, a delta-like ligand 3 (DLL3)-targeting radio-designed ankyrin repeat protein (DARPin) drug candidate. The ongoing US multi-centre trial aims to assess the safety and early efficacy of the drug. LOA and…
Molecular Partners and Orano Med have dosed the first patient in the Phase I/IIa trial assessing MP0712, a DLL3-targeting radio-DARPin drug candidate.
Source: Clinical Trials Arena